1 Medicine Network launched the world's first diabetes new drug Hua Tangning ®

On November 8, the world's first innovative drug glucokinase activator huatanginin (generic name: dopagliatin ® tablets) was officially released
on 1 drug network.
At present, a box of 28 tablets of Hua Tangning ® is priced at 420 yuan
on 1 medicine network.

Hua Tangning ® was independently developed by Hua Medicine and obtained the marketing approval
of the State Medical Products Administration on October 8.
As the world's first glucokinase activator drug approved for marketing, Huatang Ning ® has attracted much attention
.
Clinical studies have shown that Huatangning ® can repair the damaged glucokinase sensor function of diabetic patients, improve the patient's ability to regulate blood glucose, and is expected to control the progression and complications of type 2 diabetes from the source, and has the potential to
relieve diabetes discontinuation.
At the same time, Huatangning ® is an oral hypoglycemic drug that can be used for patients with type 2 diabetes with different degrees of renal impairment, and patients with renal insufficiency do not need to adjust the dose
.
Its launch offers new treatment options
for the treatment of patients with type 2 diabetes.

With its outstanding advantages in the intelligent supply chain system and as a digital platform for the omni-channel commercialization of drugs, 1 Drug Network quickly completed the introduction and achieved nationwide coverage of new drugs, greatly improving the accessibility of new drugs, and providing the possibility and convenience
for more patients with type 2 diabetes to contact new treatment options.

Up to now, 1 Medicine Network has formed a fulfillment and distribution network through seven major operation centers covering the country, which can be delivered to more than 890 cities
across the country within 24 hours.
On this basis, 1 drug network has achieved cold chain coverage in 276 cities in 29 provinces across the country, and more than 80% of cities have achieved 48-hour delivery, which can efficiently meet the different drug purchase needs
of users in various regions of the country.

In recent years, the number of people with diabetes has been on the rise
worldwide.
According to the 2021 International Diabetes Federation (IDF) 10th edition of the Global Diabetes Overview, the total number of diabetes patients in the world reached 537 million in 2021, and 1 in 10 adults aged 20-79 had diabetes, while the number of diabetes patients in China has exceeded 140 million.

The duration of diabetes is long, traditional out-of-hospital management is difficult to cover the whole course of the disease, and sugar control depends on the daily self-management of patients, which makes it difficult to ensure
patients' medication compliance.
In order to improve the daily management efficiency of diabetic patients, 1 Medicine Network and pharmaceutical companies have created a one-stop management platform centered on diabetic patients, using technology as a tool to break through time and geographical restrictions, provide convenience for doctors and patients, help patients renew prescriptions online, provide medication guidance and post-diagnosis services from professional doctors, and patients can also obtain medication reminders and various relevant information
in the field of diabetes.
In this way, the self-management ability of diabetic patients is continuously improved, and the health level of
patients is further improved.

Wang Liang, vice president of 1 Medicine.
com, said that 1 Pharma will continue to establish a professional patient management platform for diseases with large patient groups and high social value through "Internet +", improve the efficiency of information reach, and achieve more refined patient services and more efficient drug
accessibility.